Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals(vol 105, pg 1477,2019)

被引：0
|
作者：
Rathore, Saurabh Singh [1 ]
机构：
[1] Mahatma Gandhi Cent Univ, Dept Biotechnol, East Champaran, India
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年
关键词：
D O I：
10.1002/cpt.3395
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：1
相关论文
共 36 条
  • [21] A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
    Takeuchi, Fumihiko
    McGinnis, Ralph
    Bourgeois, Stephane
    Barnes, Chris
    Eriksson, Niclas
    Soranzo, Nicole
    Whittaker, Pamela
    Ranganath, Venkatesh
    Kumanduri, Vasudev
    McLaren, William
    Holm, Lennart
    Lindh, Jonatan
    Rane, Anders
    Wadelius, Mia
    Deloukas, Panos
    [J]. PLOS GENETICS, 2009, 5 (03):
  • [22] Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
    Jorgensen, Andrea L.
    FitzGerald, Richard J.
    Oyee, James
    Pirmohamed, Munir
    Williamson, Paula R.
    [J]. PLOS ONE, 2012, 7 (08):
  • [23] Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis
    Zhang, Jinhua
    Chen, Zhijie
    Chen, Chunmei
    [J]. META GENE, 2016, 9 : 197 - 209
  • [24] Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population
    Dhakchinamoorthi Krishna Kumar
    Deepak Gopal Shewade
    Marie-Anne Loriot
    Philippe Beaune
    Jayaraman Balachander
    B. V. Sai Chandran
    Chandrasekaran Adithan
    [J]. European Journal of Clinical Pharmacology, 2014, 70 : 47 - 56
  • [25] Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population
    Kumar, Dhakchinamoorthi Krishna
    Shewade, Deepak Gopal
    Loriot, Marie-Anne
    Beaune, Philippe
    Balachander, Jayaraman
    Chandran, B. V. Sai
    Adithan, Chandrasekaran
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (01) : 47 - 56
  • [26] RESPONSIVENESS OF VERY LOW-DOSE WARFARIN ASSOCIATED WITH GENETIC VARIANTS OF VKORC1, CYP2C9, CYP4F2 AND CYP2C19 IN INDONESIAN PATIENTS.
    Rusdiana, T.
    Araki, T.
    Nakamura, T.
    Subarnas, A.
    Yamamoto, K.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S62 - S63
  • [27] ACENOCOUMAROL DOSING ALGORITHM INCLUDING CLINICAL, DEMOGRAPHIC AND PHARMACOGENETIC DATA (CYP2C9, VKORC1, CYP4F2 AND APOE) FOR USE IN PATIENTS WITH THE THROMBOEMBOLIC DISEASE
    Borobia, A. M.
    Lubomirov, R.
    Ramirez, E.
    Lorenzo, A.
    Campos, A.
    Fernandez-Capitan, C.
    Frias, J.
    Carcas, A. J.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 28 - 28
  • [28] Effect of VKORC1 and CYP2C9 variants on dosage of oral anticoagulants in Chilean individuals (vol 143, pg 1369, 2015)
    Benavides, Felipe
    Grossman, Nicole
    Poggi, Helena
    Nieto, Elena
    Bertran, Antonio
    Araos, Daniel
    Vasquez, Marcos
    Ibarra, Ignaz
    Caceres, Felipe
    Espinoza, Karena
    Lagos, Marcel
    Repetto, Gabriela M.
    [J]. REVISTA MEDICA DE CHILE, 2016, 144 (01) : 138 - 138
  • [29] A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism
    Wells, P. S.
    Majeed, H.
    Kassem, S.
    Langlois, N.
    Gin, B.
    Clermont, J.
    Taljaard, M.
    [J]. THROMBOSIS RESEARCH, 2010, 125 (06) : E259 - E264
  • [30] Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients
    Wakamiya, Takuya
    Hokosaki, Tatsunori
    Tsujimoto, Shin-ichi
    Kadota, Keisuke
    Nakano, Yusuke
    Watanabe, Shigeo
    Iwamoto, Mari
    Yanagimachi, Masakatsu
    Ito, Shuichi
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2016, 20 (04) : 393 - 400
1234